Amicus Therapeutics (FOLD) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.

Do insiders and institutionals believe in FOLD or EXEL?

85.3% of Exelixis shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk and volatility, FOLD or EXEL?

Amicus Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Is FOLD or EXEL more profitable?

Exelixis has a net margin of 24.04% compared to Amicus Therapeutics' net margin of -10.62%. Exelixis' return on equity of 23.52% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-10.62%	12.44%	2.60%
Exelixis	24.04%	23.52%	17.95%

Which has higher earnings and valuation, FOLD or EXEL?

Exelixis has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$528.30M	5.31	-$151.58M	-$0.18	-50.72
Exelixis	$2.17B	4.98	$521.27M	$1.77	21.78

Do analysts rate FOLD or EXEL?

Amicus Therapeutics currently has a consensus target price of $16.75, indicating a potential upside of 83.46%. Exelixis has a consensus target price of $37.24, indicating a potential downside of 3.41%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	1 Sell rating(s)	8 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer FOLD or EXEL?

Exelixis received 86 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 72.98% of users gave Amicus Therapeutics an outperform vote while only 68.51% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%
Exelixis	Outperform Votes 618 68.51%	Underperform Votes 284 31.49%

Does the media refer more to FOLD or EXEL?

In the previous week, Exelixis had 29 more articles in the media than Amicus Therapeutics. MarketBeat recorded 34 mentions for Exelixis and 5 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.24 beat Exelixis' score of 0.52 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	16 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats Amicus Therapeutics on 12 of the 18 factors compared between the two stocks.